Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JGWZO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN119343374A ADC-S426
|
|||||
| Synonyms |
ADC-S426
Click to Show/Hide
|
|||||
| Organization |
BYONDIS B.V.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Cysteine-maleimide conjugation
|
|||||
| Combination Type |
LD2
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.594 ug/ml | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
To investigate the effect of the masked ADC - S423 on cell viability after demasking with MMP2 protease, the cytotoxicity of the masked and demasked (MMP2 - treated) ADC - S423 and ADC - S426 was tested on HER2 - positive SK - BR - 3 cells, and compared with that of the naked (unmasked) trastuzumab - based ADC - TRA41C and the isotype - control ADC - RIT41C. After 6 days of treatment, cell viability was measured using the CellTiter - GloTM (CTG) luminescent assay kit.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 82.01 ug/ml | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
To investigate the effect of the masked ADC - S423 on cell viability after demasking with MMP2 protease, the cytotoxicity of the masked and demasked (MMP2 - treated) ADC - S423 and ADC - S426 was tested on HER2 - positive SK - BR - 3 cells, and compared with that of the naked (unmasked) trastuzumab - based ADC - TRA41C and the isotype - control ADC - RIT41C. After 6 days of treatment, cell viability was measured using the CellTiter - GloTM (CTG) luminescent assay kit.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||